AA
ALXN

Apriem Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Apriem Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-100
Closed -$19K – 599
2014
Q4 		$19K Hold
100
– – 0.01% 307
2014
Q3 		$17K Hold
100
– – 0.01% 323
2014
Q2 		$16K Hold
100
– – 0.01% 298
2014
Q1 		$15K Hold
100
– – 0.01% 323
2013
Q4 		$13K Hold
100
– – 0.01% 334
2013
Q3 		$12K Hold
100
– – 0.01% 339
2013
Q2 		$9K Buy
+100
New +$9.64K ﹤0.01% 344

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Apriem Advisors's ALXN Position: Q1 2015 in Review

Apriem Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2015, closing a stake of 100 shares — an estimated $19K sold.

Apriem Advisors first reported a position in ALXN in Q2 2013 and held it in 7 quarters. The position peaked at $19K in Q4 2014. 566 funds tracked by Wall St. Rank hold ALXN as of Q1 2015.

  • Apriem Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Apriem Advisors sold 100 Alexion Pharmaceuticals shares in Q1 2015, an estimated $19K.
  • Apriem Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 7 quarters.
  • Apriem Advisors's Alexion Pharmaceuticals position peaked at $19K in Q4 2014.
  • 566 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2015.

Based on Apriem Advisors's 13F filing for Q1 2015, filed 7 May 2015.